





Amerigroup STAR+PLUS MMP (Medicare-Medicaid Plan) expands specialty pharmacy precertification list

Effective for dates of service on and after January 1, 2021, the specialty Medicare Part B drugs listed in the table below will be included in our precertification review process. Federal and state law, as well as state contract language and CMS guidelines, including definitions and specific contract provisions/exclusions, take precedence over these precertification rules and must be considered first when determining coverage. Noncompliance with new requirements may result in denied claims.

HCPCS or CPT® code	Medicare Part B Drugs
C9055	Injection, brexanolone 1 mg
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg
J1627	Injection, granisetron, extended-release, 0.1 mg
J2797	Injection, rolapitant, 0.5 mg
J9153	Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine
J9295	Injection, necitumumab, 1 mg
J9352	Injection, trabectedin, 0.1 mg
Q2049	Injection, doxorubicin hydrochloride, liposomal, imported Lipodox, 10 mg
Q2050	Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
Q5107	Injection, bevacizumab-awwb, biosimilar, (Mvasi), 10 mg
C9047	Injection, caplacizumab-yhdp, 1 mg
J9351	Injection, topotecan, 0.1 mg
Q2043	Sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion
J7208	Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl, (jivi), 1 i.u.

https://providers.amerigroup.com/TX

TXDPEC-0886-20 513190FLPENSHP September 2020